Saturday, December 3, 2022

561.316.3330

Biotechnology News Magazine

The RSA Group Reports New Study Highlights Talent Needed to Grow the Biosimilars Sector

Latest Posts

Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 1 Study of Bomedemstat in Combination with Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia

Venetoclax is a BCL-2 inhibitor approved by the U.S. Food and Drug Administration (FDA) for treatment of several hematologic cancers, including in combination with azacytidine for elderly patients with AML unable to tolerate the standard of care.

Acer Therapeutics Announces $1.5M Private Placement

The proceeds from the private placement will be used by Acer Therapeutics for working capital and general corporate purposes and, together with Acer’s existing cash and cash equivalents, are expected to be sufficient to fund the Company’s anticipated operating and capital requirements through the fourth quarter of 2022.

AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development

Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “The selection of ACI-35.030 for further development is a significant step for this collaboration. Early clinical testing showed that ACI-35.030 was generally well tolerated and induced specific activity against the pathological species of Tau, including the neurotoxic pTau and enriched paired helical filaments (ePHF) species, both of which are closely implicated in Alzheimer’s disease (AD).

TransCode Therapeutics Announces eIND Submission to US FDA for Planned First-in-Human Clinical Trial in Patients with Advanced Solid Tumors

The planned clinical trial is to evaluate TransCode’s lead therapeutic candidate, TTX-MC138, in cancer patients with advanced solid tumors. ​TTX-MC138 is designed to inhibit the pro-metastatic RNA, microRNA-10b, described as the master regulator of metastasis in a number of advanced solid tumors. TransCode Therapeutics believes that TTX-MC138 could be used as a treatment for many of these cancers.

The RSA Group, a leading life sciences executive search firm, has published the latest of its Talent Equity® Reports: Biosimilars 2022.

The new report features interviews with leaders of biosimilars companies who give their unique insights into the challenges and opportunities facing this fast-growing sector and the leadership needed to grow the industry, including the power of creating strong in-house knowledge and evaluating where this talent already exists.

Kristian Juergensen, Chief Commercial Officer at The RSA Group, explained, “There are already several large and established biosimilars players. As treatment becomes more diverse and patient care more personalised, cost-effectiveness matters more. This could close opportunities for some new players. The time to invest in biosimilars is now and that starts with your talent portfolio.”

The report shows how as this industry expands and evolves, the leaders of today will drive the successes of tomorrow. The industry is seeing seismic shifts as pharmaceutical companies invest billions of dollars in acquisitions, mergers and organic growth. New technologies are coming forward as academic and biotechnology companies innovate, and talent is emerging from both channels.

The investment in biosimilars development and production is causing a paradigm shift in the way that patients can access life-saving treatments. Although the main goal is to lower the costs of biologic treatments, the biosimilars market is bringing a host of additional benefits. By embracing technological breakthroughs and the benefits offered by biotech 4.0, biosimilars developers are not only delivering cost benefits through efficiencies and increased yields, but they are also offering new indications for greater market access, as well as more effective products with fewer side effects.

Recruiting and nurturing talent is incredibly important as biosimilars continue their rapid evolution and as more diverse and complex originator products are released and fall into the biosimilars pipeline. However businesses choose to develop, manufacture, or sell their products, one thing is certain: developers will need a core team of highly experienced and educated talent to ensure market growth and create the leaders of tomorrow.

Read the full report here.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine